Informations sur le produit
- EMD-61753
- Asimadoline [INN]
- Benzeneacetamide, N-((1S)-2-((3S)-3-hydroxy-1-pyrrolidinyl)-1-phenylethyl)-N-methyl-alpha-phenyl-
- Benzeneacetamide, N-(2-(3-hydroxy-1-pyrrolidinyl)-1-phenylethyl)-N-methyl-alpha-phenyl-, (S-(R*,R*))-
- Benzeneacetamide, N-[(1S)-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-1-phenylethyl]-N-methyl-α-phenyl-
- Benzeneacetamide, N-[2-(3-hydroxy-1-pyrrolidinyl)-1-phenylethyl]-N-methyl-α-phenyl-, [S-(R*,R*)]-
- Emd 61753
- N-((alpha S)-alpha-((3S)-3-Hydroxy-1-pyrrolidinyl)methyl)benzyl)-N-methyl-2,2-diphenylacetamide
- N-((alphaS)-alpha-(((3S)-3-Hydroxy-1-pyrrolidinyl)methyl)benzyl)-N-methyl-2,2-diphenylacetamide
- N-[(1S)-2-[(3S)-3-Hydroxy-1-pyrrolidinyl]-1-phenylethyl]-N-methyl-α-phenylbenzeneacetamide
- Voir d'autres synonymes
- N-{(1S)-2-[(3S)-3-hydroxypyrrolidin-1-yl]-1-phenylethyl}-N-methyl-2,2-diphenylacetamide
- Unii-D0Vk52Nv5M
Asimadoline (EMD-61753) is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt, Germany. Asimadoline was originally developed to treat peripheral pain such as arthritis. Asimadoline is an orally administered agent that acts as a kappa opioid receptor agonist. It has shown encouraging clinical efficacy for the treatment of IBS in a barostat study in IBS patients and has the potential for treating other gastrointestinal diseases.
Propriétés chimiques
Question d’ordre technique sur : TM-T4633 Asimadoline
Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages